Pfizer Mega-Merger Pursuit Overshadows Consumer Slump
This article was originally published in The Tan Sheet
Executive Summary
The firm’s overall performance – revenues down 9% to $11.4 billion and net income down 15% to $2.3 billion – underscores how much Pfizer needs to acquire AstraZeneca after disclosing its pursuit of the U.K. pharma.
You may also be interested in...
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.
Australian Teeth Whitener Marketer Frowns On Industry Self-Regulation Referencing US Laws
HiSmile appeals NAD recommendation following review on P&G challenge to discontinue ad claims on its website and in social media videos stating peroxide-containing whitening products are “painful” or cause pain, break down and impact gums and teeth, or “damage” gums.